Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 3.7% - Time to Sell?
Eyepoint Pharmaceuticals (NASDAQ:EYPT) saw its stock price fall by 3.7% to $12.90 on Monday, with a significant 94% drop in trading volume compared to its average. Despite weak company fundamentals, including missed quarterly earnings and revenue expectations, analysts largely maintain a "Buy" rating with a consensus target price of $32.20. Institutional investors have been actively adjusting their positions, with several major firms increasing their stakes in the biopharmaceutical company.
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT
Aberdeen Group plc significantly increased its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 101.6% in the fourth quarter, bringing its total holdings to 1,605,984 shares valued at approximately $29.34 million. This move highlights strong institutional interest, with 99.41% of the company's shares owned by institutional investors. Despite recent EPS misses and negative profitability, the stock maintains an average "Buy" rating from analysts with a mean target price of $32.20.
EyePoint Inc (EYPT) Stock Price Quote Today & Current Price Chart
This entry appears to be a stub or a link to a financial platform. It indicates a focus on providing current stock price quotes and charts for EyePoint Inc (EYPT). The reference to "Online Trading with Smart Investment App | Capital.com" suggests that Capital.com is the source or platform for this information.
Discipline and Rules-Based Execution in EYPT Response
Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT) is showing weak near and mid-term sentiment, posing a challenge to its long-term positive outlook. The analysis from Stock Traders Daily's Quantitative Research Desk highlights elevated downside risk due to a lack of additional long-term support signals. Three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—have been generated by AI models, tailored to different risk profiles and holding periods, with specific entry, target, and stop-loss levels.
EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race
EyePoint Pharmaceuticals has filed a lawsuit against Ocular Therapeutix, alleging a "malicious campaign" of defamation related to their competing retinal disease drugs. EyePoint claims Ocular disseminated false and misleading information about Duravyu to boost the standing of its own drug, Axpaxli, despite receiving warnings. EyePoint is seeking an injunction, a public retraction, and unspecified damages.
EyePoint files a lawsuit against Ocular (EYPT:NASDAQ)
EyePoint has filed a lawsuit against Ocular Therapeutix in a Massachusetts federal court. The lawsuit alleges that Ocular Therapeutix made false claims regarding its lead candidate, Duravyu. The legal action is between two rival eye drug developers.
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
EyePoint has filed a lawsuit against Ocular Therapeutix, accusing its rival of spreading false or misleading information about EyePoint and its experimental eye drug, Duravyu. The complaint, filed in Middlesex County Superior Court for the Commonwealth of Massachusetts, alleges defamation, commercial disparagement, and violations of consumer protection law. Both companies are developing treatments for serious retinal diseases like wet age-related macular degeneration.
A Look At EyePoint Pharmaceuticals (EYPT) Valuation Following Recent Mixed Share Price Performance
EyePoint Pharmaceuticals (EYPT) has shown mixed recent performance, with a 7% share price increase over the last month but declines over three months and year-to-date, despite a strong long-term return. The company is currently considered 62.5% undervalued, with analysts setting a price target of approximately $37 per share, significantly above its current trading price of $13.90, largely due to expectations for its DURAVYU product. However, its high Price/Sales ratio compared to the industry average indicates potential valuation risk.
Eyepoint Pharmaceuticals pursues new therapies as anti-VEGF treatments fall short for DME patients
Eyepoint Pharmaceuticals is advancing its Phase 3 program for diabetic macular edema (DME) to address the limitations of existing anti-VEGF therapies. The company aims to develop more durable treatments that also tackle inflammation, filling a significant gap in current solutions for patients. These efforts are part of Eyepoint’s broader strategy to enhance its market position and product launches, supported by recent leadership appointments.
Insider Buying: Eyepoint Pharmaceuticals (NASDAQ:EYPT) CEO Buys 1,500 Shares of Stock
Eyepoint Pharmaceuticals (NASDAQ:EYPT) CEO Jay Duker recently purchased 1,500 shares of the company's stock for $13.15 per share, increasing his direct ownership to 100,665 shares. This insider buying occurred despite the company missing its recent quarterly earnings and revenue expectations. Analysts, however, generally maintain a "Buy" rating with a consensus price target of $32.20 for EYPT.
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus
EyePoint Pharmaceuticals (EYPT) is conducting the COMO phase 3 study to evaluate its new eye drug, EYP-1901, for treating diabetic macular edema (DME). This trial compares EYP-1901 against aflibercept, a standard treatment, focusing on vision outcomes. The success of this long-acting tyrosine kinase inhibitor could significantly impact the treatment landscape for DME and provide a competitive advantage for EyePoint Pharma over existing anti-VEGF therapies.
Guggenheim reiterates EyePoint stock rating on Duravyu safety data
Guggenheim has reiterated a Buy rating and a $68.00 price target for EyePoint Inc. (NASDAQ:EYPT) shares, based on favorable safety data for its Duravyu treatment. The firm highlighted Duravyu's superior safety profile compared to a competitor product, Axpaxli, and noted that EyePoint is expected to be first to market. Despite recent stock dips, analysts like Mizuho, H.C. Wainwright, and Chardan have also maintained or raised their price targets for EYPT, citing progress in clinical trials and a strong cash position.
EyePoint (EYPT) Issues Stock Options to New Employees as Hiring Incentives
EyePoint Pharmaceuticals (EYPT) has granted non-statutory stock options to six new employees as an incentive, aligning with NASDAQ Listing Rule 5635(c)(4). These options, with an exercise price of $13.20 and a ten-year term, vest over four years, requiring continuous employment. EyePoint, a clinical-stage biopharmaceutical company focused on retinal diseases, shows strong liquidity and low debt but struggles with declining revenue and profitability, alongside insider selling despite a positive analyst outlook.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. (Nasdaq: EYPT) announced that it granted non-statutory stock options to six new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options allow the purchase of up to 20,000 shares of EyePoint common stock at an exercise price of $13.20 per share, vesting over four years. This initiative is part of the company's commitment to developing therapeutics for serious retinal diseases, with their lead candidate, DURAVYU, currently in Phase 3 trials.
Parkman Healthcare Partners Acquires New Stake in EyePoint Pharmaceuticals
Parkman Healthcare Partners has acquired a significant stake in EyePoint Pharmaceuticals, investing $19.88 million in 1,088,033 shares during Q4 2025, signaling strong confidence in the company. EyePoint's shares have surged 93% over the past year, outperforming the S&P 500, driven by optimism surrounding its DURAVYU Phase 3 trials for retinal diseases, with topline data expected mid-2026. Despite a net loss in 2025, EyePoint maintains a strong financial position, with sufficient cash to fund operations into late 2027.
Suvretta Capital Management LLC Sells 611,376 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT
Suvretta Capital Management LLC reduced its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 9% in the third quarter, selling 611,376 shares, but still holds 6,192,715 shares, making it their 10th largest holding. The company reported weaker-than-expected quarterly results with an EPS of ($0.81) and revenue of $0.62M, missing analyst estimates. Despite this, Wall Street maintains a "Buy" rating with an average price target of $32.20, and institutional ownership remains very high at approximately 99%.
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts
Analysts have assigned Eyepoint Pharmaceuticals (NASDAQ:EYPT) an average recommendation of "Buy" based on ratings from eight firms, with an average 12-month price target of $32.20. Despite this, the company recently missed quarterly earnings estimates, reporting EPS of $(0.81) against an expected $(0.78) and revenue of $0.62 million versus $1.01 million. Insider Ramiro Ribeiro sold a significant number of shares, while institutional investors hold approximately 99.41% of the company's stock.
Rosalind Advisors Inc. Acquires Shares of 650,000 Eyepoint Pharmaceuticals, Inc. $EYPT
Rosalind Advisors Inc. has acquired 650,000 shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) for approximately $9.26 million, making it a significant holding in their portfolio. Despite Eyepoint Pharmaceuticals reporting a weak quarter with missed EPS and revenue estimates, analysts maintain a "Buy" consensus rating with an average price target of $32.20. Institutional investors hold a large stake in the company, though insiders recently sold over 42,000 shares.
Jefferies Financial Group Inc. Purchases Shares of 140,000 Eyepoint Pharmaceuticals, Inc. $EYPT
Jefferies Financial Group Inc. has established a new position in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by acquiring 140,000 shares valued at approximately $1.99 million in the third quarter. While institutional investors collectively own 99.41% of the stock and analysts have a consensus "Buy" rating with an average target price of $32.20, the company faces challenges with missed quarterly EPS estimates and lower than expected revenue. An insider also sold 42,544 shares in January, and the stock recently opened down by about 3.4% at $14.92.
J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
J.P. Morgan analyst Tessa Romero maintained a Buy rating on EyePoint Pharmaceuticals (EYPT) with a price target of $33.00, citing strong clinical momentum for Duravyu approval. This comes despite a recorded quarterly revenue of $620 thousand and a GAAP net loss of $67.61 million for the company's latest quarter, and negative corporate insider sentiment with increased selling of shares. Other analysts have also adjusted price targets for EYPT, generally upwards.
Chardan raises EyePoint stock price target to $29 on cash position
Chardan has increased its price target for EyePoint Inc. (NASDAQ:EYPT) to $29 from $27, maintaining a Buy rating, based on the company's strong cash position of $306 million. The firm's confidence is driven by upbeat forward estimates following EyePoint's Q4 2025 results and upcoming Phase 3 Duravyu data in mid-2026, despite a recent decline in Q4 2025 revenue and a wider-than-expected loss per share. The stock has seen a significant 201% gain over the past year.
EyePoint stock rating maintained at Outperform by Mizuho
Mizuho reiterated an Outperform rating for EyePoint Inc. (NASDAQ:EYPT) with a $36.00 price target, citing the potential of its lead asset Duravyu and its differentiated profile compared to competitors. Despite recent stock weakness presenting a buying opportunity, the company reported a significant revenue decrease and a larger-than-anticipated loss per share in Q4 2025, although it holds a strong cash position. Other analysts, H.C. Wainwright and Chardan, also raised their price targets based on progress in clinical trials and financial updates.
(EYPT) Movement Within Algorithmic Entry Frameworks
This article analyzes EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) using algorithmic entry frameworks. It highlights a weak near-term sentiment but positive sentiment overall, with specific long, breakout, and short trading strategies provided. The analysis includes multi-timeframe signals, support and resistance levels, and risk-reward ratios for potential movements.
Eyepoint Pharmaceuticals, Inc. $EYPT Holdings Trimmed by Blue Owl Capital Holdings LP
Blue Owl Capital Holdings LP significantly reduced its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 34.7% in the third quarter, while institutional ownership overall remains high at 99.41%. Despite the weak recent fundamental performance of Eyepoint, including an EPS and revenue miss, analysts generally maintain a "Buy" rating with an average price target of $31.50, with some recent upgrades to "strong-buy." Insider Ramiro Ribeiro also sold a substantial number of shares, indicating mixed sentiment towards the company.
EyePoint Pharmaceuticals Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations
EyePoint Pharmaceuticals, Inc. has undergone an evaluation revision due to fluctuating market conditions, marked by significant year-over-year growth but a decline in year-to-date performance. Technical indicators show a mixed outlook, with both bullish and bearish sentiments depending on the timeframe. The company's stock has shown high volatility, outperforming the S&P 500 over the past year but lagging in year-to-date returns.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS
Eyepoint Pharmaceuticals (NASDAQ:EYPT) reported a Q4 EPS of ($0.81), missing analyst estimates by $0.03, with revenue of $0.62 million against an expected $1.01 million. Despite the earnings miss and a 6.9% drop in share price, the company's DURAVYU Phase 3 trials for wet AMD and DME are progressing, with a cash runway extending into Q4 2027. Analysts have largely maintained "Buy" ratings and raised price targets, reflecting optimism about the clinical pipeline.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $30.00
HC Wainwright recently raised its price target for Eyepoint Pharmaceuticals (NASDAQ:EYPT) to $30.00 from $23.00, maintaining a "buy" rating with a potential upside of 66.67%. Despite this, the company's Q4 results missed EPS and revenue estimates, and it remains unprofitable, though Phase 3 DURAVYU trials are on track for mid-2026 topline data with over $300 million in cash. The average analyst target price for EYPT is $31.50, with most firms rating the stock as "Buy."
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 Earnings Call Transcript
EyePoint Pharmaceuticals reported its Q4 and full-year 2025 financial results, with an EPS miss of $-0.81426 against expectations of $-0.78. The company highlighted significant progress on its lead asset, DuraVu, for wet AMD and DME, with Phase 3 trials underway and top-line data expected in mid-2026 for wet AMD and 2027 for DME. EyePoint emphasized DuraVu's compelling clinical profile, favorable safety, potential for six-month dosing, and a unique multi-mechanism of action targeting VEGF, PDGF, and IL-6.
Chardan Raises Price Target on EyePoint Pharmaceuticals to $29 From $27, Keeps Buy Rating
Chardan has increased its price target for EyePoint Pharmaceuticals (NASDAQ: EYPT) to $29 from $27, while maintaining a 'Buy' rating on the stock. This adjustment comes shortly after EyePoint Pharmaceuticals reported its Q4 2025 earnings, where it experienced a widening net loss and a drop in revenue, missing analyst estimates. The company, a clinical-stage biopharmaceutical organization, focuses on developing ophthalmic products for eye diseases leveraging its Durasert technology.
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop
EyePoint Pharmaceuticals (EYPT) reported a significant revenue drop for Q4 2025, falling 94.8% to $0.6 million from $11.6 million in Q4 2024, and announced an EPS miss at -$0.81 against a forecast of -$0.75. The decline is attributed to the end of deferred revenue recognition, while operating expenses increased due to ongoing clinical trials for DURAVYU. Despite the financial setbacks, the company maintains a strong cash position, expecting to fund operations into Q4 2027 as it progresses with pivotal Phase 3 trials for DURAVYU in wet AMD and DME.
Eyepoint Pharmaceuticals Q4 Earnings Call Highlights
Eyepoint Pharmaceuticals discussed progress on its lead retinal candidate DURAVYU, including the dosing of first patients in Phase 3 DME trials and anticipated top-line wet AMD data in mid-2026. The company reported $306 million in cash and investments at year-end 2025, which is expected to fund operations into Q4 2027, despite a decline in 2025 revenue and increased operating expenses due to Phase 3 activities. DURAVYU is being developed as a potential six-month intravitreal treatment with a multi-MOA profile, and its safety has been consistent across prior studies.
EyePoint (EYPT) Q4 2025 Earnings Call Transcript
EyePoint (EYPT) reported sharply lower Q4 2025 revenue due to deferred revenue reversal, while significantly increasing R&D and operating expenses to advance its late-stage pipeline. The company's lead asset, DuraVu, is progressing in Phase 3 trials for wet AMD and DME, with top-line data expected in mid-2026 and 2027, respectively. EyePoint confirmed a strong cash position of $306 million, sufficient to fund operations into 2027, and has strengthened its commercial leadership and manufacturing readiness for potential future approvals.
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
EyePoint, Inc. announced its financial results for Q4 and full-year 2025, highlighting progress in its DURAVYU clinical programs for wet AMD and DME, with data readouts expected in mid-2026 and 2027 respectively. The company appointed a new Chief Commercial Officer and reported over $300 million in cash and investments, providing a runway into Q4 2027. Despite increased R&D expenses due to ongoing Phase 3 trials, EyePoint is advancing its innovative sustained delivery treatment for serious retinal diseases.
EyePoint (Nasdaq: EYPT) deepens 2025 loss while pushing DURAVYU into Phase 3
EyePoint, Inc. reported a wider net loss in 2025 and Q4 2025 due to increased investment in its lead retinal drug candidate, DURAVYU, specifically for its Phase 3 trials in wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Despite the financial setbacks, the company maintains a strong cash position of $306 million, expected to fund operations into Q4 2027, covering key Phase 3 milestones. The DURAVYU trials are progressing as planned, with topline data for wet AMD anticipated in mid-2026 and for DME in the second half of 2027, positioning DURAVYU for potential future market launch.
EyePoint Pharmaceuticals to Announce Q4 Earnings on March 4
EyePoint Pharmaceuticals (EYPT) is scheduled to release its Q4 earnings report on March 4, with analysts forecasting a 17.2% year-over-year decline in EPS to -$0.75 and a significant 91.3% drop in revenue to $1.01 million. These declining expectations highlight ongoing profitability challenges and market competition difficulties for the company. Analyst sentiment is mixed, with one upward and one downward EPS revision in the past three months, contributing to market uncertainty.
Eyepoint Pharma earnings up next as pivotal trial data looms
Eyepoint Pharmaceuticals Inc. is set to release its fourth-quarter earnings, with investor focus primarily on the company's progress toward crucial mid-2026 pivotal trial data readouts for Duravyu, its investigational treatment for wet age-related macular degeneration and diabetic macular edema. Analysts rate the stock as a strong buy, anticipating significant upside despite recent stock weakness and a competitive landscape shift, as the company needs to maintain financial runway to reach these make-or-break catalysts.
EyePoint begins dosing in phase 3 DME trials for DURAVYU
EyePoint, Inc. has commenced dosing in two global phase 3 clinical trials, COMO and CAPRI, for its investigational drug DURAVYU (vorolanib intravitreal insert) aimed at treating diabetic macular edema (DME). DURAVYU, a sustained-delivery small-molecule VEGF receptor inhibitor, is administered via a single-dose, twice-yearly intravitreal injection. The trials will evaluate the safety and efficacy of DURAVYU compared to aflibercept, with topline data expected in the second half of 2027.
EyePoint Starts Global Phase 3 Trials for DURAVYU
EyePoint Pharmaceuticals has initiated global Phase 3 trials (COMO and CAPRI) for its drug DURAVYU, targeting diabetic macular edema (DME), aiming to demonstrate non-inferior vision outcomes to aflibercept with less frequent dosing. These trials, alongside existing Phase 3 programs for wet AMD, position DURAVYU as a potential first-in-class sustained-release therapy for major retinal diseases. Topline data for wet AMD is expected mid-2026, and DME in the second half of 2027, which could significantly strengthen EyePoint's market position.
Is EyePoint (EYPT) Recasting Its Ophthalmology Playbook With a Veteran Launch Executive at DURAVYU?
EyePoint, Inc. recently appointed Michael Campbell as Chief Commercial Officer to lead the commercial strategy and launch preparation for DURAVYU, its Phase 3 retinal disease candidate. Campbell's extensive experience with successful ophthalmology drug launches is crucial for EyePoint, as the company's investment narrative heavily relies on DURAVYU's commercial success before cash burn becomes overwhelming. While this hire targets key short-term catalysts and links trial progress with commercialization, the central risk remains potential delays or disappointments in pivotal trials for a company with minimal current revenue.
EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint, Inc. (Nasdaq: EYPT) announced its participation in several upcoming investor conferences, including the TD Cowen 46th Annual Health Care Conference and the Barclays 28th Annual Global Healthcare Conference. The company will discuss its innovative therapeutics for serious retinal diseases, particularly its lead product candidate, DURAVYU™, which is undergoing Phase 3 trials. Webcasts of presentations will be available on the company's investor relations website.
EyePoint Pharmaceuticals Opens with 11.81% Gain, Outperforming S&P 500's 0.69% Increase
EyePoint Pharmaceuticals, Inc. saw an 11.81% increase in its stock price, outperforming the S&P 500, but faces significant financial challenges. The company reported declining net sales, negative operating cash flow, and a high debt-equity ratio for four consecutive quarters. Additionally, promoter confidence has decreased, with a 0.63% reduction in their stake over the last quarter.
EyePoint Pharmaceuticals Hits Day High with 11.22% Surge in Stock Price
EyePoint Pharmaceuticals, Inc. (EYPT) experienced an 11.22% surge in its stock price, reaching an intraday high of USD 17.74, significantly outperforming the S&P 500. While the company has shown a remarkable 177.24% increase over the past year, it faces substantial challenges including declining net sales, negative operating cash flow, and a high debt-equity ratio. Promoter confidence also appears to be waning, with a 0.63% reduction in their stake over the last quarter.
Eyepoint Pharmaceuticals (EYPT) to Release Earnings on Wednesday
Eyepoint Pharmaceuticals (NASDAQ:EYPT) is scheduled to release its Q4 2025 earnings before market open on Wednesday, March 4th, with analysts forecasting a loss of ($0.78) per share and revenue of $1.006 million. The company's stock opened at $17.05, and analysts currently hold a "Buy" consensus rating with an average price target of $29.25, despite some insider selling. Institutional investors have a very high ownership of approximately 99.4% in the biopharmaceutical company.
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
EyePoint, Inc. announced it will report its fourth quarter and full-year 2025 financial results on March 4, 2026, via a conference call and live webcast. The company, focused on innovative therapeutics for retinal diseases, will also provide updates on recent corporate developments, including its lead product candidate DURAVYU™.
EyePoint, Inc. to Host Conference Call on March 4, 2026, to Discuss Q4 and Full-Year 2025 Financial Results
EyePoint, Inc. announced a conference call and live webcast for March 4, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and recent corporate developments. The company is advancing DURAVYU™, an investigational sustained delivery treatment for serious retinal diseases, through pivotal Phase 3 trials. Topline data for wet age-related macular degeneration is expected in mid-2026, and dosing for diabetic macular edema is set to begin in Q1 2026.
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
EyePoint, Inc. (Nasdaq: EYPT) announced it will host a conference call and live webcast on March 4, 2026, at 8:30 a.m. ET, to discuss its fourth quarter and full-year 2025 financial results and recent corporate developments. The company is actively developing DURAVYU™, an investigational sustained delivery treatment for serious retinal diseases, which is currently undergoing Phase 3 pivotal trials for wet age-related macular degeneration and diabetic macular edema. This announcement provides details for investors to access the live event and learn more about EyePoint's progress.
EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint, Inc. announced its management will participate in several upcoming investor conferences in March 2026, including the TD Cowen 46th Annual Health Care Conference, Barclays 28th Annual Global Healthcare Conference, Jefferies Biotech on the Beach Summit, and RBC Capital Markets Virtual Ophthalmology Conference. These engagements will involve fireside chats and one-on-one investor meetings. The company also highlighted its lead product candidate, DURAVYU, an investigational sustained delivery treatment for serious retinal diseases, which is currently in Phase 3 pivotal trials.
EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) announced its management will participate in several upcoming investor conferences in March 2026, including the TD Cowen Health Care Conference, Barclays Global Healthcare Conference, Jefferies Biotech on the Beach Summit, and RBC Capital Markets Virtual Ophthalmology Conference. The company will discuss its innovative therapeutics for serious retinal diseases, including its lead product candidate DURAVYU™. Webcasts of presentations will be available on EyePoint's investor relations website.
EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint, Inc. (Nasdaq: EYPT) announced its management will participate in several upcoming investor conferences in March 2026, including the TD Cowen, Barclays, Jefferies, and RBC Capital Markets events. These participations will include fireside chats and one-on-one investor meetings. The company is focused on developing and commercializing therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU™, currently in Phase 3 pivotal trials.
Patient Square Capital LP Sells 340,998 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT
Patient Square Capital LP reduced its stake in Eyepoint Pharmaceuticals, Inc. by 25.2% in the third quarter, selling 340,998 shares and now holding 1,011,839 shares valued at $14.41 million. Despite this sale, analysts maintain a "Buy" rating for EYPT with a consensus target price of $29.25, and institutional ownership remains high at 99.41%. The company, with a market cap of $1.27 billion, focuses on biopharmaceutical therapies for ocular diseases.
